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Abstract
Background: The African Programme for Onchocerciasis Control has proposed provisional thresholds for the
prevalence of microfilariae in humans and of L3 larvae in blackflies, below which mass drug administration
(MDA) with ivermectin can be stopped and surveillance started. Skin snips are currently the gold standard test
for detecting patent Onchocerca volvulus infection, and the World Health Organization recommends their use to
monitor progress of treatment programmes (but not to verify elimination). However, if they are used (in transition
and in parallel to Ov-16 serology), sampling protocols should be designed to demonstrate that programmatic goals
have been reached. The sensitivity of skin snips is key to the design of such protocols.
Methods: We develop a mathematical model for the number of microfilariae in a skin snip and parameterise it
using data from Guatemala, Venezuela, Ghana and Cameroon collected before the start of ivermectin treatment
programmes. We use the model to estimate sensitivity as a function of time since last treatment, number of
snips taken, microfilarial aggregation and female worm fertility after exposure to 10 annual rounds of ivermectin
treatment.
Results: The sensitivity of the skin snip method increases with time after treatment, with most of the increase
occurring between 0 and 5 years. One year after the last treatment, the sensitivity of two skin snips taken from an
individual infected with a single fertile female worm is 31 % if there is no permanent effect of multiple ivermectin
treatments on fertility; 18 % if there is a 7 % reduction per treatment, and 0.6 % if there is a 35 % reduction. At
5 years, the corresponding sensitivities are 76 %, 62 % and 4.7 %. The sensitivity improves significantly if 4 skin snips
are taken: in the absence of a permanent effect of ivermectin, the sensitivity of 4 skin snips is 53 % 1 year and 94 %
5 years after the last treatment.
Conclusions: Our model supports the timelines proposed by APOC for post-MDA follow-up and surveillance
surveys every 3–5 years. Two skin snips from the iliac region have reasonable sensitivity to detect residual infection,
but the sensitivity can be significantly improved by taking 4 snips. The costs and benefits of using four versus two
snips should be evaluated.
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Background
Onchocerciasis intervention programmes in Africa chan-
ged their focus from reducing skin and ocular morbidity
associated with the infection - and therefore controlling
the disease as a public health problem - to eliminating
the infection reservoir [1, 2], after both mathematical
models of transmission [3] and field studies [4–6]
showed that local elimination of Onchocerca volvulus
can be achieved through community-directed treatment
with ivermectin (CDTI). The current goal is to eliminate
onchocerciasis in selected African countries by 2020 [7]
and in 80 % of endemic countries by 2025 [8].
In response to the focus on elimination, the African
Programme for Onchocerciasis Control (APOC) has
proposed provisional parasitological and entomological
thresholds for stopping CDTI [9]. Specifically, APOC
has suggested that CDTI can be stopped if, 11–12
months after the last ivermectin treatment round, mi-
crofilarial prevalence (i.e. the proportion of people with
O. volvulus microfilariae in the skin based on two iliac
crest skin snips) is lower than 5 % in all surveyed villages
and lower than 1 % in 90 % of the villages, and the
prevalence of infective vectors (simuliid flies) is less than
0.5 infective flies per 1000 flies. Once treatment has
stopped, APOC recommends that a follow-up survey is
conducted after 3 years, and then regular surveillance
every 3–5 years. Although still advocating parasitological
testing using skin snips for monitoring progress towards
elimination, the World Health Organization (WHO) has
recently released guidelines [10], proposing that PCR-
based xenomonitoring in blackfly samples and seroposi-
tivity to the Ov-16 antigen in children aged < 10 years
should be used to demonstrate interruption of transmis-
sion for the purpose of stopping treatment. Certification
of elimination will therefore probably be based on ento-
mological and serological evaluations. Nonetheless in
African countries approaching elimination, a modifica-
tion of the “skin snip method” that was employed by the
Onchocerciasis Control Programme in West Africa
(OCP) [11, 12] remains the cornerstone of epidemio-
logical evaluations of infection prevalence. For example,
between 2008 and 2015, 58 APOC-led CDTI projects
underwent epidemiological evaluations using the skin
snip protocol [6, 13]. Indeed, a WHO/APOC document
on alternative treatment strategies for accelerating pro-
gress towards elimination in Africa [14], released in De-
cember 2015, reiterates the practice of skin snipping to
monitor progress towards elimination and confirm when
treatment can be safely stopped without excessive risk of
infection recrudescence (so-called phase 1a and phase
1b evaluations, respectively).
Although other diagnostics for patent infection (i.e.
presence of macrofilariae capable of producing micro-
filariae) are available - notably the 'diethylcarbamazine
(DEC) patch test' and the detection of O. volvulus DNA
in skin snips via polymerase chain reaction (PCR) [15–
20] - and despite limitations [19, 21, 22], the skin snip
method is still considered the gold standard for diagnos-
ing patent infection and measuring the number of O.
volvulus microfilariae in the skin.
Typically two skin snips are taken with a 2-mm Holth-
type corneoscleral punch and incubated in a suitable
medium (usually saline), ideally for 24 hours [23]. In
Africa, both snips are taken from the iliac crest (hip). In
Meso- and South American foci, a shoulder-scapular-
snip has sometimes replaced one of the iliac crest snips
in view of the greater density of microfilariae in the
upper torso in areas with upper body biting vectors [24,
25]. After incubation, the microfilariae that have
emerged from the snips are counted using an inverted
microscope and reported as the arithmetic or geometric
mean per snip (mf/ss). When the snips are weighed, the
mean number of microfilariae is expressed per mg of
skin (mf/mg).
As is the case for all diagnostic tests, the accuracy of
the skin snip method is determined by its sensitivity (the
probability that an infected individual tests positive) and
specificity (the probability that an uninfected individual
tests negative). The specificity of the skin snip method is
likely to be close to 100 %, unless the microfilariae from
other filarial parasites (e.g. Mansonella streptocerca, also
skin-dwelling, and M. perstans and M. ozzardi, which
are blood-dwelling) are incorrectly identified as O. volvu-
lus. The sensitivity, however, is less than 100 % and de-
pends on a number of factors, including the number of
snips examined, the number of fertile female worms har-
boured, the distribution of microfilariae in the skin, the
snip incubation medium and duration, the host immune
response, and the thoroughness with which the sample
is examined under the microscope [20–22, 26–30].
When an individual has received treatment, the sensitiv-
ity also depends on the anti-onchocercal drug used and
the time since treatment. In the context of evaluating
CDTI, the impact of ivermectin treatment on the sensi-
tivity is of particular interest.
In this study we use a mathematical model to predict
the sensitivity of the skin snip method in a hypothetical
community that has received CDTI. We use our model
to explore how many skin snips should be taken to
monitor progress towards elimination and to suggest
when post-treatment surveillance surveys should be
done.
Methods
Study areas and parasitological methods for the datasets
analysed
We used data collected from four studies. Two were
conducted in Latin America - in the central focus of
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Guatemala in the vicinity of Lake Atitlán [24] and in the
Amazonian focus of southern Venezuela [31, 32], and
two were conducted in Africa - in the Volta region of
Ghana [33] and in the Kumba region of Cameroon [34].
Meso-American setting
The Guatemalan data were collected as part of a study
to assess the impact of 6-monthly ivermectin treatment
on the prevalence, intensity of infection, and transmis-
sion in the central Guatemalan onchocerciasis focus [24,
35]. We used data from the pre-treatment, baseline, sur-
vey, which was conducted in May 1988. The study in-
cluded the villages of Los Andes, Los Tarrales, Santa
Emilia, El Vesubio and Santa Isabel (for an epidemio-
logical description of this focus prior to mass drug
administration with ivermectin see Brandling-Bennett
et al. [36]). A map indicating the location of these com-
munities is available in Fig. 1 of Collins et al. [24]. For
the analyses presented here, we excluded data from El
Vesubio because of its small population size and from
Santa Isabel because there was poor compliance with
skin snipping in this village.
South-American setting
The Venezuelan data were collected during an epidemio-
logical survey of onchocerciasis among Yanomami
communities in the Amazonian onchocerciasis focus
[30–32]. A map indicating the location of the study
communities is provided in Fig. 1 of [31]. We used data
from 14 villages that contributed to the Venezuelan
study, namely Aweitheri, Cerrito, Hasupiwei, Hokotopi-
wei, Kumamasi, Mahekoto, Maiyotheri, Maweti, Pasho-
pëka, Purimatheri, Toothothopiwei, Yepropë, Yoreashiana
A and Yoreashiana B.
African forest setting
The Ghanaian data were collected in a baseline survey
for a randomised trial designed to assess the safety of
moxidectin as a treatment for O. volvulus infection [33].
The study was conducted before CDTI, and participants
were recruited from onchocerciasis endemic villages in a
forest area within the River Tordzi basin in the Volta
Region of Ghana. Ninety percent of participants came
from the villages of Honuta-Gbogame, Kpedze-Anoe,
Togorme, Aflakpe, Luvudo, Kpoeta-Ashanti and Hoe,
the remainder came from 11 other villages in the area. A
map indicating the location of the villages is shown in
Fig. 3 of [33]. At the time of the study (2006), the area
was not included in the CDTI strategy of the National
Onchocerciasis Control Programme because overall it
was classified as hypoendemic in the Rapid Epidemio-
logical Mapping of Onchocerciasis (REMO) [33]. The
few meso- and hyperendemic villages would have been
missed by the survey.
The Cameroonian data were collected in a hyperen-
demic forest area of Kumba in southwest Cameroon
before the implementation of CDTI. The study partici-
pants had not previously received ivermectin, and were
born or had resided for more than 10 years in the
villages of Marumba I, Marumba II, Boa Bakundu,
Bombanda and Bombele [34].
In the Guatemalan and Venezuelan studies, two skin
snips were taken from each participant: one from the left
shoulder and the other from the left iliac crest. In Ghana
and Cameroon, one skin snip was taken from each calf
and iliac crest (i.e. four skin snips in total). In all studies,
a 2.0-mm corneoscleral Holth or Walser punch was used
to obtain the samples. In Guatemala,Venezuela and
Cameroon only the Holth corneoscleral punch was used,
while in Ghana both types of punch were used. The
samples were subsequently incubated for 24 h, or at least
8 h (overnight) in Ghana, in physiological saline solu-
tion. Although the incubation time in Ghana was less
than in the other studies, according to [23] 97 % of the
microfilariae would have emerged after 8 h of incuba-
tion. The methods used for counting microfilariae and
processing and weighing skin snips are described in [33,
36, 37]. Table 1 summarises demographic and parasito-
logical characteristics of the participants in these studies.
Modelling the sensitivity of skin snips
To estimate the sensitivity of the skin snip method we
must model both the density and distribution of micro-
filariae in the skin. If microfilariae are randomly distrib-
uted in the skin, then we can use the Poisson
distribution to calculate the sensitivity directly from the
density of microfilariae. For example, if a single 2-mg
skin snip is taken from an individual who has on average
0.5 microfilariae per mg of skin, then the expected
number of microfilariae in the sample (m) is 0.5 × 2 = 1.
And, from the Poisson assumption, it follows that the
probability the skin snip contains no microfilariae is
exp(-m) = exp(-1) = 0.37 and the probability the sample
contains one or more microfilariae, i.e. the sensitivity, is
1–0.37 = 0.63.
However, microfilariae are unlikely to be randomly dis-
tributed in the skin (e.g. the density may depend on the
distribution of fertile worms in the body). If the distribu-
tion is non-random because microfilariae occur in
“clumps”, then this will affect the sensitivity of skin snips
because the chance that a snip contains no microfilariae
is increased. To allow for this, we can use the negative
binomial model rather than the Poisson to model the
distribution of microfilariae in the skin. This distribution
is specified by an additional parameter, k, which mea-
sures the degree of aggregation, i.e. the extent of the
clumping. The distribution is approximately Poisson
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when k is large, but becomes more aggregated (overdis-
persed) as k gets closer to 0. Continuing the example of
m = 1 above, if k = 0.4 then from the negative binomial
distribution the probability the skin snip contains no
microfilariae is 1þ mk
 −k ¼ 0:61 and the sensitivity is
therefore 1–0.61 = 0.39.
Below we first estimate the extent to which microfilar-
iae are aggregated in the skin (i.e. we estimate the k par-
ameter) using existing data that were collected prior to
widespread ivermectin treatment. We then use this esti-
mate, together with a model of microfilarial density after
treatment, to estimate the sensitivity of the skin snip
methodology after treatment. The model of microfilarial
density is parameterised using estimates for pre-treatment
microfilarial production, resumption of microfilarial pro-
duction after treatment and microfilarial mortality that
have been reported elsewhere [38–42].
A mathematical model of the number of microfilariae per
skin snip before treatment
We model the number of microfilariae, xij, in the i th
skin snip from site j (shoulder, iliac crest or calf ) as an
immigration-death process. According to this model,
microfilariae arrive in the skin at a body site-specific rate
εj
* per milligram of skin per fertile female worm and die
at per capita rate μm [43, 44]. In individuals who have
not received anti-microfilarial treatment, the number of
microfilariae in a skin snip follows a Poisson distribution
with mean mij
* given by mij
* = dijwεj
*/μm, where dij is the
weight of the skin snip and w the number of fertile
female worms harboured by the host.
The rate at which microfilariae arrive at the skin is
likely to vary according to the location of the skin snip
[45]. This is because adult worms (macrofilariae) are ag-
gregated into onchocercal nodules (onchocermata),
which are themselves not evenly distributed within the
body and vary in their distribution among individuals
[38, 46]. We represent this additional variability by a
scaling factor that has a gamma distribution with mean
one and shape parameter km, which we apply to mij
* . It
follows that the marginal, pre-treatment distribution of
microfilarial load per skin snip follows a negative bino-
mial distribution with mean mij
* and dispersion param-
eter km. For skin snips taken from a host harbouring w
fertile female worms, the probability of sampling xij
microfilariae in the i th skin snip biopsy from site j is
therefore
pðxijjwÞ ¼ Γ km þ xij
 
xij !Γ kmð Þ 1 þ
mij
km
 − km þ xijð Þ mij
km
 xij
;
ð1Þ
where Γ(z) is the gamma function.
Fitting the model to pre-treatment data
We used the method of maximum likelihood to estimate
the parameters of the model from data on pre-treatment
microfilarial loads. The model was fitted separately to
data from each country.
The probability of the microfilarial loads observed
in a single host can be obtained by averaging over
the (unobserved) distribution of fertile female worms
(w), assuming it follows a negative binomial distribu-
tion within each village [40], with mean θw and dis-
persion parameter kw:X
w
Y
ij
p xij wj Þ p wð Þ:
 ð2Þ
And the probability of the data as a whole- i.e. the
likelihood - is the product of these probabilities. We
estimated the model parameters by maximising the
logarithm of this likelihood using the maxLik package
in R [47]. Specifically, we used the likelihood to esti-
mate, θw and kw in each village, the ratio of body
site-specific microfilarial production (α = ε1
* /ε2
* ), and
Table 1 Demographic and parasitological characteristics of the datasets used to parameterise the model
Country No. of villages na Median (Interquartile range)
age (years)
% Female Location of skin snips Mean microfilarial
load (mf/mg skin)
Mean weight of
skin snips (mg)
References
Guatemala 3 1,067 19 (10, 36) 44.2 1 shoulder & 1 hip shoulder = 26.3
hip = 25.4
shoulder = 1.35
hip = 1.80
[24]
Venezuela 14 613 22 (12, 35) 39.8 1 shoulder & 1 hip shoulder = 14.2
hip = 31.9c
shoulder = 1.32
hip = 1.73
[30–32]
Ghana 18 172b 17–60b 18.2–31.1 2 hip & 2 calf hip = 27.4
calf = 16.6c
hip = 2.15
calf = 2.14
[33]
Cameroon 5 2,528 17 (10, 35) 49.1 2 hip & 2 calf or
2 calf
hip = 8.0
calf = 9.5
Not weighedd [34]
an, number of individuals whose skin snip data were used in the model
bParticipants were allocated to four treatment groups. The mean age in the four groups ranged from 32.1 to 38.3 years. The table indicates the minimum and
maximum age across all treatment groups
cP-value for comparison of microfilarial load between the two body sites: P < 0.001 Venezuela; P < 0.001 Ghana
dSkin snips were not weighed in Cameroon, so it was assumed that a skin snip taken from the hip weighed 2.2 mg, and that one taken from the calf weighed
2.1 mg based on the data from Ghana
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the aggregation of microfilariae in the skin (km). Since
the latter depends on the number of fertile female
worms [46, 48], we allowed km to depend on w and
obtained estimates for 1–10, 11–30 and > 30 fertile
female worms.
The data could not be used to estimate the rate of mi-
crofilarial mortality or the rate at which microfilariae ar-
rive in the skin. We therefore fixed μm = 0.8 per year [38,
39] and ε* = (ε1
* + ε2
* ) /2 = 1.154 per year [41]. The latter
represents the average of the two body site-specific rates
in an untreated individual (shoulder and iliac crest in
Guatemala and Venezuela, and calf and iliac crest in
Ghana and Cameroon), and the value was obtained by
scaling the average annual rate of microfilarial produc-
tion per female worm per mg of skin presented in [39]
by the reciprocal of the proportion of females that are
fertile [40].
Sensitivity of multiple skin snips as a test for infection
with O. volvulus
To predict the sensitivity of the skin snip method when
used in a population that has been treated with ivermec-
tin, we consider a person infected with a single fertile fe-
male worm and model the effect of treatment with
ivermectin on the density of microfilariae in the person’s
skin. Together with the estimate of microfilarial aggrega-
tion in the skin, we use the microfilarial density to pre-
dict the probability that a skin snip contains one or
more microfilariae. This model of sensitivity implicitly
assumes that all microfilariae that emerge from the skin
snip are detected, although in practice the sensitivity will
also depend on how thoroughly the sample is examined
under the microscope.
Microfilaricidal and embryostatic effects of ivermectin
Treatment with ivermectin has two effects on the num-
ber of microfilariae found in the skin. First, microfilariae
are paralysed and move to deeper body organs where
they are destroyed (the so-called microfilaricidal ef-
fect). This results in the almost total clearance of
microfilariae from the skin within the first one or two
months of treatment. Second, adult female worms
temporarily stop producing live microfilariae, as newly
produced microfilariae are blocked inside the uterus
(the so-called embryostatic effect). This leads to the
suppression of microfilaridermia for several months
[40], although the rate at which microfilariae dis-
appear from and reappear in the skin differs some-
what between individuals [33].
The embryostatic effect is well documented, but it is
unclear whether microfilarial production eventually
returns to its original level or whether the fertility of
some adult female worms is permanently impaired after
each treatment [41, 43, 49–53]. Plaisier et al. [49] test
two hypotheses for the effect of ivermectin on microfi-
larial production: the first assumes that treatment has
only a transient effect on the microfilarial production;
the second assumes that in addition to the transient ef-
fect, ivermectin also causes a permanent reduction in
microfilarial production.
We allow for both possibilities by assuming that after
exposure to n rounds of ivermectin a fertile female
worm resumes production and release of microfilariae at
rate (1 − ζ)nεj
*, after a period of time that is exponentially
distributed with rate ρ = 0.29 year−1 [40, 42], where ζ is
the per dose reduction in fertility caused by the treat-
ment. According to this model, there is a permanent as
well as a transient effect when ζ > 0, but only a transient
effect when ζ = 0. Based on these assumptions, the ex-
pected rate of microfilarial production at time t after the
last dose of ivermectin is
εj tð Þ ¼ 1−ζð Þnεj 1− exp −ρ tð Þ½ : ð3Þ
And the expected number of microfilariae in a skin
snip skin taken from an individual infected with a single
female worm t years after the last treatment is
mij tð Þ ¼
dij 1−ζð Þnεj
μm ρ−μmð Þ
ρ 1− exp −μmtð Þ½ −μm 1− exp −ρ tð Þ½ f g :
ð4Þ
If we assume that the microfilarial load in a skin snip
follows a negative binomial with mean mij(t), and de-
note the event that any of the skin snips are positive by
x+(t), then the sensitivity of a test for onchocerciasis
that combines multiple skin snips taken t years after
the last treatment is
p xþ tð Þjw ¼ 1  ¼ 1 − Π
i
Π
j
pðxij tð Þ ¼ 0j w ¼ 1Þ
¼ 1 − Π
i
Π
j
1 þ mij tð Þ
km
 −km
:
ð5Þ
When infection with more than one fertile female
worm is rare - mathematically this is the case when θw/
kw < < 1 - the proportion of the population that tests
positive is approximately the product of the sensitivity
and the proportion infected, since
p xþð Þ ¼ Σ
w
p xþjwð Þp wð Þ
≈ p xþjw ¼ 1ð Þp w ¼ 1ð Þ
≈ p xþjw ¼ 1ð Þp w > 0ð Þ: ð6Þ
We use eqn [5] to investigate three scenarios for the im-
pact of treatment with ivermectin on sensitivity: 1) treat-
ment does not have a cumulative effect on microfilarial
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production (ζ = 0) [43]; 2) treatment reduces microfilarial
production by 7 % per dose (ζ = 0.07) [54]; and 3) treatment
reduces microfilarial production by 35 % per dose (ζ = 0.35)
[42, 49, 55]. We further assume that in a hypothetical com-
munity that has received prolonged CDTI, a fertile female
worm has been exposed to n = 10 annual treatment rounds.
This number of treatments was chosen because the repro-
ductive life span of female worms is 9–11 years [56], so
under annual CDTI it is unlikely that a worm is exposed to
a greater number of treatments. (Under a biannual treat-
ment strategy, a worm can be exposed to twice the number
of treatments, but we do not explore this scenario.) The
model parameters are defined in Table 2.
Results
Model parameter estimates
We fitted the model to skin snip data collected from
4,380 individuals before community-wide distribution of
ivermectin; 46 % were female and the median age was
18 years (interquartile range, IQR: 10–35 years, Table 1).
The model-estimated mean burden of fertile female
worms and aggregation varied considerably between vil-
lages, particularly in Venezuela, where the mean burden
was 0.4/host in Yepropë and 50 in Aweitheri, and kw
varied from 0.02 (most aggregated) in Yepropë to 0.59
(least aggregated) in Pashopëka (Table 3). In contrast,
the aggregation of microfilariae in the skin was similar
across the countries and there was a consistent pattern
of increased aggregation with decreasing worm burden
(i.e. microfilariae were less evenly distributed in the skin
at low worm burdens). Across the 4 studies, the average
aggregation parameter for skin microfilariae, km, was
0.42 for 1–10 female worms, 0.76 for 11–30 worms and
1.82 for > 30 female worms.
Sensitivity of 1, 2, 4 and 6 skin snips t years after the last
ivermectin treatment
We used the average aggregation in microfilarial load (km
= 0.42), estimated from the pre-treatment data for infec-
tions of 1–10 fertile female worms, and eqns [4] and [5] to
predict the sensitivity of 1, 2, 4 and 6 skin snips (assuming
a weight of 2 mg per snip) taken from an individual in-
fected with a single fertile female worm t years after the
last ivermectin treatment. Apart from km, the parameter
values used in eqn [4] (i.e. ε*= 1.154 per worm per mg of
skin per year; μm= 0.8 per year, and ρ = 0.29 per year) were
estimated in previous studies (Table 2).
We found that the sensitivity of one or more skin
snips increases with time after treatment, with most of
the increase occurring between 0 and 5 years (Fig. 1).
This is because the rapid and almost complete clearance
of microfilariae soon after treatment is followed by the
Table 2 Notation, definition and values of model parameters
Symbol Definition Value and units References
xij Number of microfilariae in the ith skin snip biopsy from body site j
(shoulder, hip or calf)
Data from each participant [24, 30–34]
dij Weight of the i th skin snip biopsy from body site j (shoulder, hip or calf) See Table 1, in mg [24, 30–33]
ε* Rate of production of microfilariae per (mated) fertile worm per mg of skin 1.1538 year-1 [41]
mij
* Mean number of microfilariae per skin snip at baseline For the mean number of mf/mg for
each site and setting see Table 1
km Aggregation (overdispersion) parameter of skin microfilariae Estimated by fitting the model, see Table 3
μm Per capita rate of microfilarial mortality 0.8 year-1 [38, 39]
w Number of adult (mated) fertile female worms harboured by the host Unobserved, assumed to be linearly related
to microfilarial load
[39]
θW Mean number of adult (mated) fertile female worms per host Unobserved, estimated by fitting the
model, see Table 3
kW Aggregation (overdispersion) parameter of adult female worms Estimated by fitting the model, see Table 3
α = ε1*/ε2* Ratio of the rate of microfilarial arrival in a shoulder or calf skin snip to
the rate in a snip from the iliac crest
Estimated by fitting the model, see Table 3
ρ Rate of resumption of microfilarial production 0.29 year-1 [40, 42]
t Time since last ivermectin treatment 1, 3, 5 years
ζ The per dose reduction in female worm fertility caused by ivermectin treatment 0 [43]
0.07 [54]
0.35 [55]
n No. of (annual) ivermectin rounds to which a surviving (mated) female worm
has been exposed
10
x+ The event that any of the skin snips taken from a host are positive
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Table 3 Parameter estimates obtained by fitting a model for the number of microfilariae in a skin snip to data collected in four
countries (notation as in Table 2)
Guatemala Venezuela Ghana Cameroon
Aggregation of microfilariae as a function of (unobserved) female
worm burdena
km
1–10 adult female worms 0.35 (0.27, 0.46) 0.48 (0.32, 0.73) 0.54 (0.41, 0.70) 0.29 (0.26, 0.32)
11–30 adult female worms 0.60 (0.47, 0.76) 0.50 (0.31, 0.80) 1.25 (1.01, 1.55) 0.69 (0.56, 0.85)
>30 adult female worms 1.42 (1.13, 1.78) 1.35 (1.00, 1.82) 2.75 (1.74, 4.34) 1.77 (1.45, 2.17)
Mean burden of fertile female worms (range across villages) θW 15–19 0.4–50 15b 5–16
Aggregation of female worm burden (range across villages) kW 0.38–0.52 0.02–0.59 2.27
b 0.31–0.50
Ratio of microfilarial arrival rate in the two body
sites sampled per setting (relative to iliac crest)a
α 1.08 (0.95, 1.22)
(shoulder/hip)
0.34 (0.28, 0.43)
(shoulder/hip)
0.57 (0.49, 0.66)
(calf/hip)
1.0 (0.81, 1.21)
(calf/hip)
aEstimates presented with 95 % Wald confidence interval
bToo few data per village for village-specific estimates
Fig. 1 Sensitivity of 1, 2, 4 and 6 skin snips (assuming a weight of 2 mg per snip) taken from an individual infected with a single, fertile female
worm. Three scenarios are explored for the effect of ivermectin on microfilarial production: (a) microfilarial production by adult female worms is
independent of the number of previous exposures to ivermectin (i.e. ζ=0 [43]); (b) each round of treatment reduces microfilarial production by
7 % (ζ=0.07 [54]); (c) each treatment round reduces production by 35 % (ζ=0.35 [55]). It is assumed that the worms have been exposed to 10
rounds of (annual) ivermectin treatment. Other parameter values are: microfilarial aggregation in the skin, km = 0.42 (mean of the country-specific
estimates for 1–10 adult female worms), pre-treatment microfilarial production per fertile female worm per mg of skin per year, ε* = 1.154 (estimate
from [41]), microfilarial mortality per year μm = 0.8 (estimate from [38, 39]), and resumption of microfilarial production per year ρ = 0.29 (estimate from
[40, 42]). The dot-dash lines correspond to 1 snip; the dashed lines to 2 snips; the solid lines to 4 snips and the dotted lines to 6 snips
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resumption of production by adult female worms, and
subsequent release of microfilariae, which increases rap-
idly up to 5 years.
The change in sensitivity thus mirrors the production of
microfilariae and consequently depends on the assump-
tions made about the impact of ivermectin on the fertility
of adult female worms. Figures 2 and 3 show how the
mean number of microfilariae per skin snip and the fre-
quency distribution of microfilariae among snips change
with time.
One year after treatment, the sensitivity of two skin
snips taken from an individual infected with a single fer-
tile female worm is 31 %, assuming no permanent effect
of multiple ivermectin treatments on fertility (ζ = 0);
18 % assuming 7 % reduction per treatment (ζ = 0.07),
and 0.6 % assuming a 35 % reduction per treatment
(ζ = 0.35). At 5 years, the estimates are 76 %, 62 %
and 4.7 %, respectively. The sensitivity improves signifi-
cantly if 4 skin snips are taken. For example, if there is no
permanent effect of ivermectin on adult female worm
reproduction, the sensitivity of 4 skin snips is 53 % 1 year
after the last treatment and 94 % at 5 years. Estimates of
the sensitivity of 1, 2, 4 and 6 skin snips at 1, 3, and 5 years
are presented in Table 4.
In Venezuela and Ghana, the density of microfilariae
was greater in skin snips taken from the iliac crest than
in snips taken from the second skin site, namely, the
scapular in Venezuela and the calf in Ghana (Table 1
and Table 3). In Additional file 1: Figure S1 and S2, we
therefore present body site-specific estimates of sensitiv-
ity for these countries, which show that sensitivity is
highest when skin snips are taken from the iliac crest.
Although our estimates of microfilarial aggregation in
the different studies were similar, they may not be
generalizable to other settings. In Additional file 1:
Figure S3 we therefore show how the sensitivity varies
for km in the range 0.01 to 1. It can be seen that skin
snips become less sensitive as the aggregation increases
(km decreases).
Microfilarial prevalence
We can use eqn [6] and estimates of skin snip sensitivity
to improve estimates of the microfilarial prevalence of
O. volvulus when infection is rare. Table 5 presents
prevalence estimates when the 2-snip skin snip method
indicates a 0.25 %, 0.5 % or 1 % microfilarial prevalence
at 1 year, 3 years and 5 years after the last ivermectin
treatment.
Fig. 2 Mean microfilarial load in a single skin snip taken from an individual infected with a single, fertile female worm. Panels (a) to (c) and
parameter values are as defined in Fig. 1
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Discussion
In this paper, we used a mathematical model of the
density and distribution of O. volvulus microfilariae in
the skin to predict the sensitivity of the skin snip
method for identifying patent O. volvulus infection in
communities that have received CDTI and where the in-
fection is close to elimination.
We fitted the model to pre-treatment skin snip data
from two Latin American [24, 31] and two African [33,
34] studies, and obtained estimates of the mean female
worm burden per person, the aggregation in worm bur-
den, the aggregation of microfilariae in skin snips, and
the ratio of microfilarial density in the two different re-
gions of the body from which the skin snips were taken.
Ideally we would have included in our analysis data col-
lected in the savannah (the African data analysed in this
paper were collected in forest foci [33, 34]), but the
available microfilarial count data (e.g. from northern
Cameroon, analysed in [39]) were aggregated across skin
snips, and the snips were not weighed. One of the differ-
ences between forest and savannah parasites is that their
microfilariae are located at different depths in the
dermis-microfilariae have a more superficial distribution
in the forest than in the savannah [57] - which might
affect skin snip sensitivity.
Our estimates of mean fertile female worm burden per
host for Guatemala (15–19) and Ghana (15) are in line
with estimates of female worm burden based on nodu-
lectomy data from a forest focus in Liberia (26 female
worms per person, including live and dead worms), and
a savannah focus in Burkina Faso (24 female worms)
[46], since approximately 60 % of female worms are fer-
tile [40]. They are also consistent with model-derived es-
timates from the same data (24 female worms in men
and 23 in women, in Liberia; 17 female worms in men
and 19 in women, in Burkina Faso) [48]. It should be
noted that the data analysed did not include observed
numbers of female worms (e.g. from data on excision of
onchocercomata (nodulectomy) or nodule palpation).
Our estimates of fertile female worm burden are indirect
estimates that have been derived assuming that there is
a linear (density independent) relationship between
worm burden and microfilarial load [41, 48, 54, 58].
The estimated aggregation of microfilariae within a skin
snip site was consistent across the four studies. However,
the skin snip data used to parameterise the model were
mainly collected from hyperendemic villages, with the ex-
ception of the Venezuela Amazonian focus where ende-
micities ranged from hypoendemic (Purima, Yepropë),
and mesoendemic (Mahekoto, Maweti, Toothothopiwei)
Fig. 3 Frequency distribution of microfilarial load among skin snips taken from an individual infected with a single, fertile adult female worm.
The vertical, y-axis, represents the proportion of snips with the number of microfilariae represented on the horizontal, x-axis. Rows correspond to
times after the last treatment with ivermectin (upper row = 1 year; middle row = 3 years; bottom row = 5 years). Panels (a) to (c) and parameter
values are as defined in Fig. 1
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to hyperendemic-and we therefore cannot be certain that
the estimated relationship between microfilarial aggrega-
tion in the skin and worm burden applies where there is a
low intensity of infection (e.g. after long-term CDTI).
Since we observed that the degree of aggregation increases
as worm burden declines, we might expect that in these
settings microfilariae are more aggregated and skin snips
are less sensitive [41, 54, 55]. In the future, we hope that
our methodology can be used to estimate the degree of
microfilarial aggregation from microfilarial count data ob-
tained from hypoendemic settings as they are incorpo-
rated into treatment programmes [59].
We estimated that the density of microfilariae was
higher in the iliac region than in the scapular region in
Venezuela, and that it was higher in the iliac region than
in the calves in Ghana. This implies that among skin snips
of comparable size taken from individuals in Venezuela
and Ghana, those taken from the iliac crest are more sen-
sitive than those taken from the other body site. And since
our data show that iliac skin snips are also heavier than
other skin snips we expect an even greater difference in
sensitivity per skin snip [21, 29]. The difference in microfi-
larial distribution across body sites was not observed in
the other two countries (Guatemala and Cameroon),
which suggests that the distribution of microfilariae across
the body varies with geographical location, and possibly
reflects the region most frequently bitten by the prevailing
simuliid vectors [60, 61].
Following [21, 29] we explored the sensitivity of 1 to 6
skin snips and confirmed that sensitivity can be greatly
improved by taking multiple skin snips. However,
Table 5 Predicted estimates of prevalence (%) of patent infection for a given (2-snip) sensitivity and observed prevalence of
microfilariae
Per ivermectin dose
reduction in microfilarial
production
1 year after last treatment 3 years after last treatment 5 years after last treatment
Sensitivitya Prevalence (%) Sensitivitya Prevalence (%) Sensitivitya Prevalence (%)
Obsb Pred Obsb Pred Obsb Pred
0 % reduction per treatment
31 % 0.25 0.8 67 % 0.25 0.4 76 % 0.25 0.3
0.5 1.6 0.5 0.7 0.5 0.7
1.0 3.2 1.0 1.5 1.0 1.3
7 % reduction per treatment
18 % 0.25 1.4 51 % 0.25 0.5 62 % 0.25 0.4
0.5 2.8 0.5 1.0 0.5 0.8
1.0 5.6 1.0 2.0 1.0 1.6
35 % reduction per treatment
0.6 % 0.25 nac 3.0 % 0.25 8.3 4.7 % 0.25 5.3
0.5 nac 0.5 nac 0.5 nac
1.0 nac 1.0 nac 1.0 nac
aSensitivity for 2 skin snips based on km = 0.42 (mean of the country-specific estimates for 1–10 adult female worms)
bObserved prevalence based on 2 skin snips
cna not applicable, we do not present predicted prevalence when greater than 10 % since eqn [6] is only valid when infection is rare
Table 4 Sensitivity of 1, 2, 4 and 6 skin snips taken 1, 3 and
5 years after the last ivermectin treatment
Sensitivity (%)a
Time after last treatment
1 year 3 years 5 years
0 % reduction in microfilarial production per treatment
Number of skin snips
1 17 42 51
2 31 67 76
4 53 89 94
6 67 96 99
7 % reduction in microfilarial production per treatment
Number of skin snips
1 10 30 38
2 18 51 62
4 33 76 85
6 45 88 94
35 % reduction in microfilarial production per treatment
Number of skin snips
1 0.3 1.5 2.4
2 0.6 3.0 4.7
4 1.3 5.8 9.2
6 1.9 8.6 13.5
aEstimates of sensitivity are based on km = 0.42 (mean of the country-specific
estimates for 1–10 adult female worms).
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communities are increasingly reluctant to participate in
skin snipping, so a compromise must be found between
what is feasible and the ideal. Currently, two un-weighed
iliac snips are taken during APOC surveys, but if four
could be taken the sensitivity of the diagnostic would be
greatly improved. For example, one and three years after
treatment, four skin snips have approximately twice and
1.5 times the sensitivity of two snips. Although we found
that taking 6 skin snips further increases sensitivity, the
extra gain is probably not sufficiently large to warrant the
greater inconvenience to the patient.
As intervention programmes progress from control to
elimination, APOC has recommended that countries
consider alternative treatment strategies [14]. In areas
where onchocerciasis is co-endemic with loiasis (African
eye worm), ivermectin CDTI needs to be implemented
with special precautions because of the risk of severe ad-
verse events among co-infected individuals [62–64].
Currently, a strategy of 'test-and-not treat', identifying
those individuals with a high microfilarial load (e.g.
≥ 30,000 microfilariae of L. loa per ml of blood), and ex-
cluding them from ivermectin treatment is being trialled
[65]. However, withdrawing treatment from this group
may prohibit onchocerciasis elimination (Stolk et al.,
unpublished results), particularly if the proportion of
non-compliers (those who consistently refuse to take
ivermectin) is already high [41, 54, 55, 58, 66]. In these
circumstances, test-and-treat protocols are required so
that co-infected individuals can be offered alternative
therapeutics. One such therapy is doxycycline (or other
tretracycline antibiotic), which has macrofilaricidal
efficacy against O. volvulus but does not affect L. loa
[67–69]. In areas where loiasis is not co-endemic with
onchocerciasis, test-and-treat strategies might be cost ef-
fective in situations where there has been prolonged
CDTI, but where elimination thresholds have not been
achieved because compliance has been poor [14].
Ideally test-and-treat strategies and surveillance should
be implemented using tests that are less invasive than
the skin snip method. The DEC-patch test ([15–18, 20]
and see also [70–72]), and Ov-16 serology [73, 74] are
two possible alternatives. The DEC patch test consists of
applying diethylcarbamazine citrate topically to a 6 cm2
area of skin. The killing of microfilariae induced by DEC
leads to a diagnostic skin reaction, which has been vali-
dated as a surrogate marker of patent infection [70–72].
A patch that uses Nivea lotion and is applied to the iliac
crest has been evaluated in central Africa and was
adopted by the OCP for surveillance [15–17], and a
patch that incorporates transdermal delivery technology
[18] was used in the recent surveillance studies in Mali
and Senegal [5]. The Ov-16 antibody test is another al-
ternative, but it has the drawback that it detects past as
well as current infection. However, it could be used to
detect recrudescence by examining people born after
the interruption of transmission [75]. For reviews of al-
ternative diagnostic methods, including biomarkers of
adult worm infection, we refer the reader to [19, 22,
73, 76].
Conclusions
An accurate test (or battery of tests) for patent O. volvu-
lus infection is required to monitor progress towards
elimination, and to implement alternative treatment
strategies. The development of such a test should be a
priority. However, the skin snip method currently re-
mains the gold standard since it is the only test that is
able to accurately quantify the intensity of infection [14,
22]. The recent WHO guidelines for stopping MDA and
verifying elimination of human onchocerciasis [10] state
that parasitological evaluation by skin snip microscopy
and the DEC-patch test can be used to monitor progress
during the first (treatment) phase of onchocerciasis
elimination programmes and, although the procedure is
not advocated to verify elimination, skin snip evaluation
by PCR is recommended to differentiate between active
infection and past exposure to the parasite in those situ-
ations where Ov-16 seropositivity is at least 0.1 %. It is
therefore important that enough skin snips are taken per
individual to diagnose O. volvulus infections reliably,
particularly if a test-and-treat strategy is to replace long-
term CDTI (e.g. in areas where targeted treatment may
be more cost effective than CDTI), or is implemented in
areas where onchocerciasis is hypoendemic.
Additional file
Additional file 1: Additional figures illustrating setting-specific sensitivity
and the influence of microfilarial overdispersion. Figure S1. Sensitivity of
the skin snip method in the Amazonian focus of southern Venezuela.
Figure S2. Sensitivity of the skin snip method in the Volta region of
Ghana. Figure S3. Sensitivity of the skin snip method under different
scenarios for the amount of microfilarial aggregation. (PDF 421 kb)
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